{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001100","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2023-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.121425+00:00","generated_at":"2026-06-20T10:40:27.589063+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Heart Test Labs amends loan; extends FRV note to Sep 2024, reduces 2023 debt payments by $1.2M","bullets":["Amendment No. 4 to Loan and Security Agreement dated Jan 24, 2023 with lenders FRV and John Q. Adams.","FRV note (original $500k) maturity extended to Sept 30, 2024; all principal and accrued interest due then.","JQA note (original $500k): accrued interest from June 28, 2022 due Sept 30, 2023; principal and later interest due March 31, 2024.","Company states amendment reduces 2023 debt and accrued interest repayment obligations by $1.2 million.","Company also releases all claims against lenders under the agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001100","json":"https://secwatch.observer/filing/0000950170-23-001100.json","markdown":"https://secwatch.observer/filing/0000950170-23-001100.md","text":"https://secwatch.observer/filing/0000950170-23-001100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023001100/0000950170-23-001100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023001100/hscs-20230124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T10:40:27.589063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eaaedd4c19dcb3ca8dc969540d7827b3d874af8","claim":"HeartSciences Inc. amended Amendment No. 4 with Front Range Ventures LLC and John Q. Adams valued at $1.2 million (effective 2023-01-24).","evidence_excerpt":"On January 24, 2023, Heart Test Laboratories, Inc. (the “Company”) entered into Amendment No. 4 (the “Amendment”) to the Loan and Security Agreement dated April 24, 2020 (the “Agreement”) by and among the Company, Front Range Ventures LLC (“FRV”) and John Q. Adams (“Adams”) which was previously amended on September 30, 2021, November 3, 2021 and May 24, 2022.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023001100/0000950170-23-001100-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Front Range Ventures LLC and John Q. Adams"},{"label":"Value","value":"$1.2 million"},{"label":"Effective","value":"2023-01-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}